Literature DB >> 15286016

Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine.

Dana E M Rollison1, William F Page, Harriet Crawford, Gloria Gridley, Sholom Wacholder, Jennifer Martin, Richard Miller, Eric A Engels.   

Abstract

Simian virus 40 (SV40) was an accidental contaminant of vaccines produced in monkey kidney tissue cultures in the 1950s and early 1960s, including a parenteral adenovirus vaccine given to several hundred thousand US military recruits. Detection of SV40 DNA in tumor tissues by some laboratories suggests that SV40 contributes to human cancers. To determine if entry into US Army service during periods of administration of SV40-contaminated adenovirus vaccine was associated with an increased risk of cancer, the authors conducted a case-control study of cancer occurring in male Army veterans who entered service in 1959-1961. Cases of brain tumors (n = 181), mesothelioma (n = 10), and non-Hodgkin's lymphoma (n = 220) were identified through a Veterans Administration hospital discharge database, as were colon cancer and lung cancer controls (n = 221). Exposure to adenovirus vaccine was assigned on the basis of known periods of adenovirus vaccine administration and dates of Army entry obtained for cancer cases and controls. The odds ratios associated with exposure to SV40-contaminated adenovirus vaccine were 0.81 (95% confidence interval (CI): 0.52, 1.24) for brain tumors, 1.41 (95% CI: 0.39, 5.15) for mesothelioma, and 0.97 (95% CI: 0.65, 1.44) for non-Hodgkin's lymphoma. These findings do not support a role for SV40 in the development of these cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15286016     DOI: 10.1093/aje/kwh212

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  8 in total

1.  Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004.

Authors:  Kevin L Russell; Anthony W Hawksworth; Margaret A K Ryan; Jennifer Strickler; Marina Irvine; Christian J Hansen; Gregory C Gray; Joel C Gaydos
Journal:  Vaccine       Date:  2006-01-24       Impact factor: 3.641

2.  Comments on the introduction of the paper "Overview of the biochemical and genetic processes in malignant mesothelioma".

Authors:  Algranti Eduardo
Journal:  J Bras Pneumol       Date:  2014-10       Impact factor: 2.624

Review 3.  Association Between Simian Virus 40 and Human Tumors.

Authors:  John Charles Rotondo; Elisa Mazzoni; Ilaria Bononi; Mauro Tognon; Fernanda Martini
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

4.  Simian virus 40 in humans.

Authors:  Fernanda Martini; Alfredo Corallini; Veronica Balatti; Silvia Sabbioni; Cecilia Pancaldi; Mauro Tognon
Journal:  Infect Agent Cancer       Date:  2007-07-09       Impact factor: 2.965

5.  Immune-related conditions and subsequent risk of brain cancer in a cohort of 4.5 million male US veterans.

Authors:  E K Cahoon; P D Inskip; G Gridley; A V Brenner
Journal:  Br J Cancer       Date:  2014-03-04       Impact factor: 7.640

Review 6.  Matrix and backstage: cellular substrates for viral vaccines.

Authors:  Ingo Jordan; Volker Sandig
Journal:  Viruses       Date:  2014-04-11       Impact factor: 5.048

Review 7.  Potential of live pathogen vaccines for defeating the COVID-19 pandemic: History and mechanism.

Authors:  Ji-Wang Chen; Ji-Ming Chen
Journal:  J Med Virol       Date:  2020-06-19       Impact factor: 20.693

Review 8.  SV40 and human mesothelioma.

Authors:  Michele Carbone; Adi Gazdar; Janet S Butel
Journal:  Transl Lung Cancer Res       Date:  2020-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.